With coronavirus cases surging, the Food and Drug Administration’s top vaccine official said Friday the agency is redeploying staff and adding computer and other technical resources to accelerate an effort to grant the Pfizer coronavirus vaccine full approval as rapidly as possible.

“We have rolled out an all hands on deck” strategy to identify ways to expedite approval of the vaccine, which is currently being administered under the FDA’s emergency use authority, said Peter Marks, director of the Center for Biologics Evaluation and Research, in an interview.

He said the center — which, in addition to overseeing vaccines, regulates biologics, stem cells and gene therapies — is “thoughtfully reprioritizing” its work to focus on the vaccine as much as possible. Pfizer received emergency authorization for its two-shot vaccine in December and applied to the FDA for full approval May 7.